About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main scientific interest is to understand, from a multidisciplinary and translational approach, the molecular and cellular processes leading to renal dysfunction in several kidney pathologies. Specifically, our research lines are
We are experts on the following areas:
To sum up, our research main objective is to combine –omic data from cellular and animal models with patients’ data to identify novel biomarkers and possible treatments for several renal diseases.
PMID: 34602313 Journal: EUROPEAN UROLOGY Year: 2022 Reference: Eur Urol. 2022 Jan;81(1):124-125. doi: 10.1016/j.eururo.2021.09.019. Epub 2021 Sep 30. Impact factor: 20.096 Publication type: Letter whit IF Authors: Morote, Juan; Diaz, Fernando; Celma, Anna; Planas, Jacques; Trilla, Enrique et al. DOI: 10.1016/j.eururo.2021.09.019
PMID: 34840098 Journal: Actas Urologicas Espanolas Year: 2022 Reference: Actas Urol Esp (Engl Ed). 2022 Jan-Feb;46(1):57-62. doi: 10.1016/j.acuroe.2021.05.004. Epub 2021 Nov 25. Impact factor: 0.994 Publication type: Paper in national publication Authors: Trilla, E; Raventos, C X; Salvador, C; Lopez-Molina, C; Carrion, A; Campistol, M; Pinero, A; Lozano, F et al. DOI: 10.1016/j.acuroe.2021.05.004
PMID: 34554648 Journal: AMERICAN JOURNAL OF TRANSPLANTATION Year: 2022 Reference: Am J Transplant. 2022 Feb;22(2):673-675. doi: 10.1111/ajt.16855. Epub 2021 Oct 5. Impact factor: 8.086 Publication type: Letter or abstract Authors: Toapanta, Nestor; Esperalba, Juliana; Campos-Varela, Isabel; Pont, Teresa; Len, Oscar; Campins, Magda; Moreso, Francesc; Crespo, Elena; Munoz, Marina; Lopez, Manuel et al. DOI: 10.1111/ajt.16855
PMID: 34352790 Journal: UROLOGIA INTERNATIONALIS Year: 2022 Reference: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5. Impact factor: 2.089 Publication type: Paper in international publication Authors: Raventos Busquets, Carles X; Semidey, M Eugenia; Lozano Palacio, Fernando; Carrion Puig, Albert; Aula Olivar, Ana; De Torres Ramirez, Ines M; Trilla Herrera, Enrique et al. DOI: 10.1159/000517543
PMID: 34610128 Journal: NEPHROLOGY DIALYSIS TRANSPLANTATION Year: 2021 Reference: Nephrol Dial Transplant. 2021 Oct 5. pii: 6381717. doi: 10.1093/ndt/gfab285. Impact factor: 5.992 Publication type: Paper in international publication Authors: Domingo-Gallego, Andrea, Pybus, Marc, Madariaga, Leire, Pinero-Fernandez, Juan Alberto, Gonzalez-Pastor, Sara, Lopez-Gonzalez, Mercedes, Simarro-Rueda, Esther, Quintanilla-Mata, Maria Luisa, Matoses-Ruiperez, Maria Luisa, Ejarque-Vila, Laia et al. DOI: 10.1093/ndt/gfab285
PMID: 34221390 Journal: Clinical Kidney Journal Year: 2021 Reference: Clin Kidney J. 2020 Dec 14;14(7):1826-1834. doi: 10.1093/ckj/sfaa265. eCollection 2021 Jul. Impact factor: 4.452 Publication type: Paper in international publication Authors: Roca, Neus, Madrid, Alvaro, Lopez, Mercedes, Fraga, Gloria, Jatem, Elias, Gonzalez, Jorge, Martinez, Cristina, Segarra, Alfons et al. DOI: 10.1093/ckj/sfaa265
PMID: 33988730 Journal: PEDIATRIC NEPHROLOGY Year: 2021 Reference: Pediatr Nephrol. 2021 Nov;36(11):3733-3740. doi: 10.1007/s00467-021-05089-6. Epub 2021 May 14. Impact factor: 3.714 Publication type: Paper in international publication Authors: Paglialonga, Fabio, Consolo, Silvia, Brambilla, Marta, Caporale, Olga, Gual, Alejandro Cruz, Grassi, Maria Rosa, Montini, Giovanni et al. DOI: 10.1007/s00467-021-05089-6
PMID: 33987651 Journal: HUMAN MOLECULAR GENETICS Year: 2021 Reference: Hum Mol Genet. 2021 Jul 9;30(15):1413-1428. doi: 10.1093/hmg/ddab131. Impact factor: 6.15 Publication type: Paper in international publication Authors: Duran, Monica, Burballa, Carla, Cantero-Recasens, Gerard, Butnaru, Cristian M, Malhotra, Vivek, Ariceta, Gema, Sarro, Eduard, Meseguer, Anna et al. DOI: 10.1093/hmg/ddab131
The communication is part of a study aimed at identifying the mechanisms of progression of Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis, a rare disease that affects the kidneys.
"Patients with familial hypomagnesemia with hypercalciuria and nephrocalcinosis present miRNA profiles in urinary extracellular vesicles associated with disease progression" was the awarded work.
Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.
